Background:
Hyperhomocysteinemia (HHcy) is an independent risk factor for atherosclerosis (AS), the molecular mechanisms of its pathogenesis are not fully understood. Endothelial dysfunction is the key initiating link in AS. However, whether endothelial-mesenchymal transition (EndMT) is involved in the regulation of HHcy-induced endothelial dysfunction and the role of catalpol in it remain unexplored.
Methods and Results:
In vitro HHcy-treated primary human umbilical vein endothelial cells (HUVECs) were used to construct a model of endothelial dysfunction, and the antioxidants N-acetylcysteine (NAC) and catalpol were administered. In vivo C57BL/6N mice were given a diet fed with 4.4% high methionine chow to construct a HHcy mice model and were treated with catalpol. The results showed that catalpol significantly inhibited HHcy-induced endothelial cell morphological transformation, reduced HHcy-induced increase in intracellular ROS content and α-SMA, N-cadherin, p-p65 protein expression, increased HHcy-induced decrease in VE-cadherin, CD31 protein expression, and was able to protect against endothelial pathological changes in the aortic root and reduce aortic endothelial ROS content.
Conclusions:
Catalpol inhibits HHcy-induced EndMT, and the underlying mechanism may be related to the ROS/NF-κB signaling pathway. Catalpol may be a potential drug for the treatment of HHcy-related AS.